Is TB-500 Legal in Pennsylvania? Federal Law, State Rules, and How to Get It
HealthRX.com
Federal materials do not establish TB-500 is legal in Pennsylvania
See the public record for TB-500
At a glance
- FDA approval / None; FDA found no approved drug containing TB-500 in the US and no approved product in Canada, Australia, the UK or the European countries it checked [1]
- What it is / A synthetic 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4 [1]
- FDA compounding lists / Not on the pharmacy list or the outsourcing-facility list [2][3][4]
- Advisory committee / Voted July 23, 2026 to add it to the pharmacy list; advice only [7][5]
- HHS draft policy / No enforcement action intended against certain compounders of TB-500 acetate if conditions are met; not an approval [5][6]
- Human data / FDA found no article in which TB-500 was given to a person [1]
- Anti-doping / WADA bans thymosin-beta4 and its derivatives, including TB-500, at all times [8][9]
What federal law says about TB-500
TB-500 is not an FDA-approved drug: FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, and no approved product in Canada, Australia, the UK or the European countries it checked [1]. It is a synthetic 7-amino-acid fragment of thymosin beta-4, and FDA found several salts and derivatives with different active moieties sold under the same name [1].
A state-licensed pharmacy may compound with a bulk drug substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that can be used in compounding [4]. TB-500 is on neither that list nor FDA's list for outsourcing facilities, and FDA's category 1 policy of generally not acting against compounders does not cover it [2][3][4]. FDA found no pharmacy marketing a compounded TB-500 product and no outsourcing facility reporting one [1].
FDA staff recommended against adding TB-500 free base or TB-500 acetate to the pharmacy list, citing poor characterization, no human data, no evidence of effectiveness for wound healing, and immunogenicity risk [1]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favor of adding it, against staff's recommendation; the advice is non-binding and listing takes formal rulemaking [7][5].
HHS filed a draft policy on October 28, 2026, scheduled for publication October 30 [5]. It names TB-500 among six peptides, covers TB-500 acetate given by subcutaneous or intramuscular injection, and says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if conditions are met, including a patient-specific prescription and a certificate of analysis [5][6]. The notice says it does not establish rights and is not binding on HHS or the public [5].
Sellers offer TB-500 as research-use-only injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]. A 'research use only' label does not mean TB-500 is FDA-approved or that its safety in people has been established [1].
What people on Reddit report
Peptide forum posts about the pending FDA advisory review of compounding lists and what it means for whether this peptide can be compounded.
You may or may not know about this but the FDA's has a meeting for July 23-24 2026 about peptides like BPC-157, KPV, TB-500, and MOTS-C for the 503A bulks list. That list determines what compounding pharmacies can legally produce.Read the source discussion
The July meeting is definitely worth watching, but it's important to remember that discussion doesn't equal approval. These peptides are currently in a regulatory grey area, not authorized and not banned. If the panel is supportive, the process of adding them to the 503A Bulks List could still take some time.Read the source discussion
Questions worth asking
Pennsylvania
The federal materials describe FDA approval status, federal compounding-list status and a draft HHS enforcement-discretion policy. They do not establish a Pennsylvania-specific rule for TB-500, so no state-level conclusion can be drawn from them [1][2][3][4][5][6]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [5].
Anti-doping status
WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times, in and out of competition, on both the 2026 and 2027 Lists [8][9].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is TB-500 legal in Pennsylvania?
Did the July 2026 advisory vote make TB-500 legal to compound?
What dose of TB-500 is used?
Is TB-500 banned in sport?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Reddit participants. FDA Peptide Meeting July 2026 BPC-157, TB-500, KPV, MOTS-C (r/BioHackingGuide). Accessed 2026-11-11.